FINWIRES · TerminalLIVE
FINWIRES

$OBIO

6 stories mentioning OBIOUpdated 3d ago

Every FINWIRES story that references OBIO, newest first.

What are analysts saying about OBIO?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on OBIO?

Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.5%.The iShares Biotechnology ETF (IBB) dropped 1.4%.In corporate news, Cooper (COO) shares fell past 13% after the company cut its fiscal 2026 guidance. Separately, BofA Securities downgraded Cooper to neutral from buy and lowered its price target to $65 from $80. BofA said Cooper could not sell CooperSurgical at an attractive valuation given competition from the Paragard intrauterine device and the fertility litigation settlement.Novartis (NVS) shareholder Artisan Partners called for changes to the Swiss drugmaker's board following two consecutive drug trial setbacks that sent shares tumbling, Reuters reported, citing an interview with Artisan managing director David Samra. Novartis shares were up 0.3%.Orchestra BioMed (OBIO) shares rose past 7% after BTIG upgraded the stock the stock to buy from neutral, with a price target of $10.BioCryst Pharmaceuticals' (BCRX) Ordaleyo faces competitive pressure in the hereditary angioedema treatment space, and its shares are expected to settle within an in-line trading range in the near term, RBC Capital Markets said in a note. RBC downgraded the company's stock rating to sector-perform from outperform and reduced the price target to $11 from $13. BioCryst shares fell 6%.

$BCRX$COO$NVS$OBIO
Sectors

Sector Update: Healthcare

Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.5%.The iShares Biotechnology ETF (IBB) dropped 1.4%.In corporate news, Orchestra BioMed (OBIO) shares rose past 10% after BTIG upgraded the stock the stock to buy from neutral, with a price target of $10.

$OBIO
Wire

Orchestra BioMed Shares Rise After BTIG Upgrade

Orchestra BioMed Holdings (OBIO) shares were up about 10% in Thursday trading after BTIG upgraded the stock the stock to buy from neutral, with a price target of $10.Trading volumes stood at more than 639,000, compared with a daily average of about 357,000.Price: $5.99, Change: $+0.54, Percent Change: +9.91%

$OBIO
Wire

Top Midday Gainers

Wealthfront (WLTH) reported fiscal Q2 earnings and sales above market expectations late Wednesday.Shares jumped 15% on Thursday as intraday trading volume climbed to more than 4.42 million from a daily average of roughly 1.47 million.Designer Brands (DBI) shares jumped 12% amid heavy trading after the company raised its full-year 2026 outlook for net sales and adjusted diluted earnings per share.More than 1.04 million shares traded intraday, compared with a daily average of about 580,000.BTIG upgraded Orchestra BioMed (OBIO) to buy from neutral with a price target of $10.Shares jumped 8%, with intraday trading volume rising to over 584,800 from a daily average of about 357,000.Price: $10.87, Change: $+1.41, Percent Change: +14.90%

$DBI$OBIO$WLTH
Research

BTIG Upgrades Orchestra BioMed to Buy From Neutral, Price Target is $10

Orchestra BioMed Holdings (OBIO) has an average rating of buy and mean price target of $12, according to analysts polled by FactSet.

$OBIO
Wire

Orchestra BioMed Gets Second FDA Breakthrough Designation for Hypertension Therapy

Orchestra BioMed (OBIO) said Thursday the US Food and Drug Administration granted a second Breakthrough Device designation for its atrioventricular interval modulation therapy.The designation covers patients with uncontrolled hypertension despite the use of antihypertensive medications, including those who are indicated for a pacemaker.Orchestra BioMed has a collaboration with Medtronic (MDT) to develop and commercialize the therapy for pacemaker-indicated patients, according to the statement.Price: $3.79, Change: $-0.01, Percent Change: -0.21%

$MDT$OBIO

Track with the FINWIRES app suite